Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.

Kang Miao,Xiaotong Zhang,Hanping Wang,Xiaoyan Si,Li Zhang

Thoracic cancer（2023）

引用 12|浏览23

暂无评分

摘要

In METex14 skipping NSCLC patients, the efficacy of savolitinib and crizotinib did not show significant difference. In MET amplification patients, savolitinib showed better efficacy than crizotinib.

查看译文

关键词

MET amplication,METex14 skipping,crizotinib,savolitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要